Back

The efficacy and safety of prolonged dual antiplatelet therapy beyond 12 months in patients with high risk of ischemic or bleeding events after PCI

13 March 2021 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Live Abstract session - Antithrombotics and bleeding Antiplatelet Drugs ACVC Premium Access ACVC 2021

About the speaker

Photo
Doctor Haoyu Wang

Fuwai Hospital, CAMS and PUMC, Beijing (China)

7 More presentations in this session

Presentation thumbnail
Trends in major bleeding events in patients with acute coronary syndrome.
Doctor A. Cordero (Alicante, ES)
Abstract
Presentation thumbnail
Long-term ischemic and bleeding risk with extended dual antiplatelet therapy after PCI in patients with 2018 ESC/EACTS myocardial revascularization guideline-endorsed high thrombotic risk features.
Doctor H. Wang (Beijing, CN)
Abstract
Presentation thumbnail
Safety and efficacy of direct oral anticoagulants (DOACs) vs warfarin in patients with concurrent atrial fibrillation and bioprosthetic mitral or aortic valve replacement-a meta analysis
Ms A. Abdul Razzack (Hyderabad, IN)
Abstract
Presentation thumbnail
Cardiovascular outcomes of clopidogrel and aspirin vs ticagrelor and aspirin in geriatric population with acute coronary syndrome-a systematic review and meta analysis
Ms A. Abdul Razzack (Hyderabad, IN)
Abstract
Presentation thumbnail
Benefit and Harm of Extended Dual Antiplatelet Therapy After PCI in high-risk TWILIGHT-like patients with acute coronary syndrome
Doctor H. Wang (Beijing, CN)
Abstract

Access the full session

Session thumbnail
Live Abstract session - Antithrombotics and bleeding

The Event

Event poster

ACVC 2021

13 March - 14 March 2021
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention
thumbnail
Congress Presentation
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources